Obviously, the combination of proteins and small-molecule drugs, such as therapeutic proteins/chemotherapeutics, therapeutic proteins/photosensitizers, and CAT/photosensitizers, results in enhanced synergistic anti-tumor effects in preclinical trials. The gene discussed is CAT; the disease is neoplasm.